Loading stock data…
$3.76+0.05 (+1.35%)
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
Evaxion A/S in the Healthcare sector is trading at $3.76 with a market capitalization of $28M. Wall Street consensus targets $12.25 (4 analysts), implying a +225.8% move over the next 12 months. The stock is currently 46% below its 52-week high of $6.92, remaining 5.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $7.49M↑ | $37,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.85M↓ | -$3.82M↑ | -$4.05M↓ | $3.02M↑ | -$4.34M |
| Net Income | -$3.73M↓ | -$3.63M↑ | -$5.92M↓ | $4.62M↑ | -$4.83M |
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based...